Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports and paid a fee for this company profile page.
Please refer to the important disclosures below for additional details.
Rocket Doctor AI reports 3,625 completed U.S. patient visits in the first two months of Q3 2026. The update highlights ongoing U.S. expansion and telehealth momentum for retail investors.
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported 3,625 completed U.S. patient visits in July and August, alongside 1,555 clinical hours as its U.S. operations expanded.
Rocket Doctor AI reports 43% revenue growth and 196% U.S. patient visit increase in Q2 2026, backed by 24 million covered lives and an expanding payer network.
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported Q2 revenue of US$734,028 as U.S. patient visits nearly tripled and its in-network coverage expanded to approximately 24 million lives.
Rocket Doctor AI enters a major provider network agreement in California covering 60 million consumers across multiple lines including workers compensation and Medicare. Learn the key details and next steps for investors.
New multi-channel partnership opens contracted entry points into workers' compensation, auto medical, and Medicare networks, further extending Rocket Doctor AI Inc.'s (AIDR:CSE; AIRDF:OTC; 939:FRA) U.S. partnering strategy.
Rocket Doctor AI expanded potential in-network access to more than 100,000 additional eligible covered lives in New York through a new payer agreement, while continuing to expand its physician network and healthcare AI capabilities in the United States.
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) recently added 100,000 eligible members in New York to its network. This expansion brings the total number of individuals with potential in-network access to the company's virtual care services to approximately 10 million in New York and 24 million across the United States.
Rocket Doctor AI extends its New York telehealth engagement through 2029, combining grants and Medicaid to serve underserved patients while scaling its AI platform amid strong digital health market growth.
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) extended its EngageWell partnership after an initial virtual-care pilot connected more than 400 underserved New Yorkers with physician-led care.
Rocket Doctor AI reaches SOC 2 Type I compliance, strengthening its enterprise position as the digital health market expands rapidly with rising AI adoption.
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) said its wholly owned Rocket Doctor platform achieved SOC 2 Type I compliance following an independent third-party audit of its security, privacy, and operational controls.
Rocket Doctor AI Inc.'s (AIDR:CSE; TREIF:OTC; 939:FRA) Clinical Decision Support System is being deployed in Alberta, Canada, on a small scale for a trial period with the goal of expanding it province-wide next year. This company's stock is rated Speculative Buy; read on to learn why.
Treatment.com AI Inc. has rebranded and reincorporated as Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) to reflect the integration of its proprietary AI-driven Global Library of Medicine (GLM) with the recently acquired Rocket Doctor Inc. Read why one analyst calls part of the company's offerings "Shopify for physicians."
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) launches virtual screening for older adults in NYC, backed by US$1M from CVS Health Foundation, as it scales AI tools and patient reach. Read more about how this initiative is helping expand access to care and driving growth in virtual health innovation.
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) launched its enhanced medical education suite in Minnesota, showing strong reliability and providing schools with up to 40% cost savings. Read on to find out how AI-simulated patients are reshaping medical education and enhancing clinical skills at scale.
Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) subsidiary Rocket Doctor was chosen by the Larta Institute to participate in its Bioscience and Healthcare Accelerator program. Read on to learn why one analyst says it is time to buy this company's stock.
Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) virtual care subsidiary, Rocket Doctor, has expanded its core virtual care services into New York and California. Separately, its virtual ER program, designed to reduce unnecessary emergency room visits, continues to demonstrate a strong impact. Over a 12-month period between 2023 and 2024, Rocket Doctor reported an 88% year-over-year increase in revenue."
Technical Analyst Clive Maund explains why he thinks now is an excellent time to buy or add to positions in Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA).
Rocket Doctor, under Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA), is now an in-network provider for New York Medicaid, expanding virtual healthcare access to 6.9 million beneficiaries. Find out how this milestone offers the possibility to reshape healthcare accessibility.
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has announced the release of its newly updated Medical Education Suite (MES). Read more to find out how this update is set to transform medical education and enhance training efficiency.
Healthcare artificial intelligence (AI) company Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has closed a non-brokered private placement for aggregate gross proceeds of CA$1.95 million. Find out why one analyst says the stock is a Strong Buy and worth going overweight on.
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) is a Strong Buy and worth being overweight on.
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has formally entered a collaborative agreement with UK-based AI healthcare technology company SPRYT Limited. Read how this partnership aims to change the way patients interact with their healthcare providers.
The parties intend to develop artificial intelligence-backed solutions to a problem in healthcare, for expanded use throughout and beyond the United Kingdom. Find out why one analyst is bullish on this company and its proprietary platform.
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) announced it will roll out a new AI (artificial intelligence) Pharmacy Assistant to support pharmacists. One analyst says the company has positioned itself as a "central go-to resource."
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has successfully seen the exercise of nearly 800,000 warrants issued on conversion of special warrants in June for gross proceeds of about CA$500,000. See why one technical analyst rates this stock a Buy as the company solidifies its investor confidence.
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has provided a general corporate update, detailing significant progress made through Q1 and Q2 of 2024. Read about what this means for the future of its platform, the Global Library of Medicine (GLM) and future projects.
Technical Analyst Clive Maund gives an update on Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) as he believes "something is going on" and the stock may be heading higher.
Treatment.com AI Inc. has entered into a collaborative agreement with Health Care Services International Inc. to leverage its advanced healthcare AI engine and enhance services. Read on to learn what this means for the growing sector.
Treatment.com AI Inc., a leader in artificial intelligence for healthcare education, has introduced two new tools for its Medical Education Suite (MES).
Canadian artificial intelligence (AI) and machine learning healthcare company Treatment.com AI Inc. is using AI to positively disrupt the healthcare sector. Canada is planning to fund the industry in a big way.
Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock.
Canadian artificial intelligence (AI) and machine learning healthcare firm Treatment.com AI is breaking into the global healthcare AI market predicted to be worth US$187 billion by the end of the decade.
9/14/2026 – Rocket Doctor AI Provides Operational Update for U.S. Operations for First Two Months of Q3 2026 Ahead of Global Company Town Hall
9/9/2026 – Rocket Doctor AI Announces Global Company Town Hall to Showcase Q2 2026 Milestones and Strategic Vision
9/1/2026 – Rocket Doctor AI Reports Strong Operational Momentum in Q2 2026 Driven by U.S. Expansion and Growing Patient Reach
8/18/2026 – Rocket Doctor Enters New Strategic Network Agreement in California to Expand Access Across Multiple U.S. Healthcare Channels
8/17/2026 – Rocket Doctor AI Inc. Announces Closing of Second Tranche of Oversubscribed Private Placement of Unsecured Convertible Debenture Financing
8/11/2026 – Rocket Doctor Expands In-Network Access for More Than 100,000 Additional Eligible Members in New York
8/5/2026 – Rocket Doctor AI joins the B2i Digital Featured Company Program and its Network of more than 1.7 million Retail and Institutional Market Participants
7/30/2026 – Rocket Doctor Extends EngageWell Partnership to Improve Healthcare Access for Underserved New Yorkers
7/23/2026 – Rocket Doctor Named One of Canada's Top 100 AI & Tech Startups for ALL IN 2026
7/21/2026 – Rocket Doctor Joins National Coalition Advocating for Permanent Medicare Telehealth
7/14/2026 – Rocket Doctor Achieves SOC 2 Type I Compliance, Reinforcing Trust, Security and Enterprise Readiness
6/30/2026 – Rocket Doctor Enters into a Primary Care Value-Based Care Agreement in the United States, Expanding In-Network Coverage by More Than 5 Million Members
Important Disclosures
Rocket Doctor AI Inc. is a Billboard advertiser of Streetwise Reports and pays a flat fee. Fees fund both sponsor-specific activities and general report activities. Sponsor-specific activities may include aggregating content and publishing that content on the Streetwise Reports site, creating and maintaining company landing pages, interviewing key management, posting a banner/billboard, and/or issuing press releases.
The fees also cover the costs for Streetwise Reports to publish and syndicate investment opinion and comments, and also to curate or create sector-specific content.
Billboard advertising monthly fees range from $3,000 to $5,000.
This landing page contains a summary of the company that was prepared by that company.
Some landing pages contain investing highlights and a catalyst calendar that are prepared by that company.
The Expert Comments and Experts Following This Company sections of the landing page are compiled by Streetwise Reports.
There may be other information about the company that is not placed on the landing page, and Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on the landing page.
Readers should conduct their own research for all information publicly available concerning the company.
This landing page may be considered advertising for the purposes of 18 U.S.C. 1734.
Restructures
A stock restructure (or capital restructure) in the context of stocks generally refers to a broader set of corporate actions that change a company's capital structure–the mix of debt and equity, or the way shares are organized and distributed. This can include changes to the number of shares outstanding, share classes, or ownership proportions.
Streetwise Company Fact Sheet
